Pfizer (PFE) Gross Margin (2009 - 2026)

Pfizer (PFE) has reported Gross Margin for 18 consecutive years, with 72.78% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Margin fell 144.0% year-over-year to 72.78% in Q2 2026; TTM through Jun 2026 was 73.18%, a 184.0% decrease from a year earlier, with the FY2025 full-year figure at 74.33%, up 238.0% from the prior year.
• Gross Margin was 72.78% for Q2 2026 at Pfizer, down from 75.45% in the prior quarter.
• Over five years, Gross Margin peaked at 79.26% in Q1 2025 and troughed at 120.24% in Q4 2023.
• A 5-year average of 59.39% and a median of 74.09% in 2025 frame the typical range for Gross Margin.
• Across the five-year window, Gross Margin plunged 1027 bps in 2022 and surged 1248 bps in 2023, its largest moves.
• Over 5 years, Gross Margin stood at 68.83% in 2022, then slumped by 275 bps to 120.24% in 2023, then jumped by 162 bps to 73.96% in 2024, then dropped by 5 bps to 69.97% in 2025, then increased by 4 bps to 72.78% in 2026.
• The last three Gross Margin figures came in at 72.78% (Q2 2026), 75.45% (Q1 2026), and 69.97% (Q4 2025), per Business Quant data.